GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Predilife SA (XPAR:ALPRE) » Definitions » LT-Debt-to-Total-Asset

Predilife (XPAR:ALPRE) LT-Debt-to-Total-Asset : 0.79 (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Predilife LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Predilife's long-term debt to total assests ratio for the quarter that ended in Jun. 2023 was 0.79.

Predilife's long-term debt to total assets ratio declined from Jun. 2022 (1.84) to Jun. 2023 (0.79). It may suggest that Predilife is progressively becoming less dependent on debt to grow their business.


Predilife LT-Debt-to-Total-Asset Historical Data

The historical data trend for Predilife's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predilife LT-Debt-to-Total-Asset Chart

Predilife Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.67 1.10 0.67 1.29 1.40

Predilife Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.12 1.29 1.84 1.40 0.79

Predilife LT-Debt-to-Total-Asset Calculation

Predilife's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )/Total Assets (A: Dec. 2022 )
=6.635/4.747
=1.40

Predilife's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (Q: Jun. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2023 )/Total Assets (Q: Jun. 2023 )
=6.796/8.618
=0.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Predilife  (XPAR:ALPRE) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Predilife LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Predilife's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Predilife (XPAR:ALPRE) Business Description

Traded in Other Exchanges
N/A
Address
114 rue Edouard Vaillant Espace Maurice Tubiana, Villejuif, Paris, FRA, 94800
Predilife SA develops solutions of predictive medicine combining proven medical techniques (genetic tests, medical imaging) and mathematical models using a large number of statistical data that could allow each individual to define his risk profile for the occurrence of a large number of serious diseases. The company markets its Mammorisk personalized breast cancer screening solution in Europe and the United States.

Predilife (XPAR:ALPRE) Headlines

No Headlines